Spots Global Cancer Trial Database for ctl
Every month we try and update this database with for ctl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). | NCT02026362 | Hepatocellular ... | MASCT:Multiple ... The foundation ... | 20 Years - 70 Years | HRYZ Biotech Co. | |
| Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | NCT01070797 | Adenovirus Infe... Epstein-Barr Vi... Cytomegalovirus... Stem Cell Trans... | Multi-virus Spe... | - | Baylor College of Medicine | |
| Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer | NCT02496273 | Gastric Cancer | CTL | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | NCT00990496 | Glioblastoma Mu... | Fludarabine Cyclophosphamid... CMV Specific Cy... | 5 Years - 65 Years | Milton S. Hershey Medical Center | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | NCT01333046 | Hodgkin Lymphom... Non-Hodgkin Lym... Hodgkin Disease | Antigen-Escalat... Dose-Escalation... azacytidine and... Pediatric multi... | 18 Years - | Baylor College of Medicine | |
| Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation | NCT02210065 | Leukemia Lymphoma | Cytomegalovirus... | 18 Years - | M.D. Anderson Cancer Center | |
| Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme | NCT01205334 | Glioblastoma Mu... GBM Brain Cancer | Autologous CMV-... | - | Baylor College of Medicine | |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | NCT01333046 | Hodgkin Lymphom... Non-Hodgkin Lym... Hodgkin Disease | Antigen-Escalat... Dose-Escalation... azacytidine and... Pediatric multi... | 18 Years - | Baylor College of Medicine | |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | NCT01333046 | Hodgkin Lymphom... Non-Hodgkin Lym... Hodgkin Disease | Antigen-Escalat... Dose-Escalation... azacytidine and... Pediatric multi... | 18 Years - | Baylor College of Medicine | |
| Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | NCT04193098 | Non-small Cell ... Second-line Tre... | CTL Toripalimab | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Novel Peptide Vaccination for Patients With Advanced Bladder Cancer | NCT00635336 | Bladder Cancer | MPHOSPH1 and DE... | 20 Years - 80 Years | Iwate Medical University | |
| A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer | NCT00995358 | Esophageal Canc... | peptide | 20 Years - 80 Years | University of Yamanashi | |
| A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer | NCT00995358 | Esophageal Canc... | peptide | 20 Years - 80 Years | University of Yamanashi | |
| Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer | NCT01592617 | Carcinoma, Non-... | S-488410 | 20 Years - 79 Years | Shiga University | |
| Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | NCT01604031 | B-cell Chronic ... | B-CLL Vaccine Lenalidomide | 18 Years - 75 Years | Baylor College of Medicine | |
| Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies | NCT05237206 | Oncology | SUPLEXA | 18 Years - | Alloplex Biotherapeutics Inc | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| Novel Peptide Vaccination for Patients With Advanced Prostate Cancer | NCT01225471 | Prostate Cancer | CDCA1 | 20 Years - 85 Years | Iwate Medical University | |
| Novel Peptide Vaccination for Patients With Advanced Bladder Cancer | NCT00635336 | Bladder Cancer | MPHOSPH1 and DE... | 20 Years - 80 Years | Iwate Medical University | |
| A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | NCT00990496 | Glioblastoma Mu... | Fludarabine Cyclophosphamid... CMV Specific Cy... | 5 Years - 65 Years | Milton S. Hershey Medical Center | |
| Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) | NCT00655785 | Pancreatic Canc... | VEGFR1-1084, VE... Gemcitabine | 20 Years - 80 Years | Fukushima Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
